Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Silence Therapeutics (SLN) Return on Equity (2021 - 2025)

Historic Return on Equity for Silence Therapeutics (SLN) over the last 5 years, with Q3 2025 value amounting to 0.77%.

  • Silence Therapeutics' Return on Equity fell 1400.0% to 0.77% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.77%, marking a year-over-year decrease of 1400.0%. This contributed to the annual value of 0.58% for FY2024, which is 16000.0% up from last year.
  • According to the latest figures from Q3 2025, Silence Therapeutics' Return on Equity is 0.77%, which was down 1400.0% from 0.8% recorded in Q2 2025.
  • In the past 5 years, Silence Therapeutics' Return on Equity ranged from a high of 0.39% in Q2 2024 and a low of 7.4% during Q1 2022
  • Moreover, its 5-year median value for Return on Equity was 1.58% (2021), whereas its average is 2.1%.
  • Per our database at Business Quant, Silence Therapeutics' Return on Equity surged by 47600bps in 2023 and then tumbled by -4100bps in 2025.
  • Quarter analysis of 5 years shows Silence Therapeutics' Return on Equity stood at 3.71% in 2021, then tumbled by -100bps to 7.4% in 2022, then surged by 64bps to 2.69% in 2023, then skyrocketed by 85bps to 0.41% in 2024, then plummeted by -88bps to 0.77% in 2025.
  • Its Return on Equity stands at 0.77% for Q3 2025, versus 0.8% for Q2 2025 and 0.63% for Q1 2025.